Previous 10 | Next 10 |
Looking For Biotech Penny Stocks Right Now? One of the most active sets of penny stocks in 2020 has been biotech stocks. Aside from the obvious push from COVID-19 vaccine candidates, companies are utilizing the increased attention to build upon novel treatment pipelines. Evidenced b...
BioLineRx Ltd. (BLRX) Q3 2020 Earnings Conference Call November 23, 2020 10:00 AM ET Company Participants Timothy McCarthy – LifeSci Advisors, LLC Phil Serlin – Chief Executive Officer Mali Zeevi – Chief Financial Officer Abi Vainstein – Vice President-Clinical Dev...
Gainers: DPW Holdings (DPW) +179%.Ideanomics (IDEX) +65%.Fuel Tech (FTEK) +61%.Greenland Technologies (GTEC) +52%.Kaixin Auto (KXIN) +52%.FuelCell Energy (FCEL) +45%.CIIG Merger (CIIC) +37%.Graybug Vision (GRAY) +36%.Beam Global (BEEM) +35%.Marathon Patent (MARA) +33%.Losers: B...
Gainers: Medigus (MDGS) +36%, 180 Life Sciences (ATNF) +35%, Graybug Vision (GRAY) +23%, Trinity Biotech (TRIB) +18%, Accuray (ARAY) +14%.Losers: Bellerophon Therapeutics (BLPH) -18%, BioLineRx (BLRX) -13%, AIM ImmunoTech (AIM) -11%, iBio...
BioLineRx (BLRX) Q3 results:Revenues: $0; R&D Expense: $3.5M (-37.5%); Net loss: ($4.6M) (-17.9%); loss/share: ($0.02) (+33.3%); Quick Assets: $20.8M ; CF Ops: ($17.8M) (+3.5%).During the quarter, the company reported interim analysis for Phase 2b BLAST study in consolidation AML that did...
Ashford Hospitality Trust (AHT) -21% on update of exchange offers for all outstanding series of preferred stock.BioLineRx (BLRX) -13% on Q3 earnings release.AIM ImmunoTech (AIM) -8% after AIM and Shionogi terminated their material transfer agreement.Niu Technologies (...
biolinerx (BLRX): Q3 GAAP EPS of -$0.02 beats by $0.32.Cash, cash equivalents and short-term bank deposits of $20.8MPress Release For further details see: biolinerx EPS beats by $0.32
BioLineRx Reports Third Quarter 2020 Financial Results and Provides Corporate Update - Phase 3 GENESIS study in SCM showed statistically significant positive results for primary endpoint in interim analysis; enrollment halted early; topline data in H1 2021 - - Interim analys...
BioLineRx (BLRX) has announced that its lead drug candidate Motixafortide, will be evaluated in an investigator-initiated Phase 1b trial in patients suffering from acute respiratory distress syndrome ((ARDS)) secondary to COVID-19 and other respiratory viral infections.The primary endpoint of...
BioLineRx to Report Third Quarter 2020 Results on November 23, 2020 PR Newswire TEL AVIV, Israel, Nov. 18, 2020 Management to hold a conference call at 10:00 a.m. EST TEL AVIV, Israel , Nov. 18, 2020 /PRNewswire/ -- BioLineRx Ltd. (NAS...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...